CNTX Context Therapeutics Inc
Price (delayed)
$0.94
Market cap
$84.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.46
Enterprise value
-$9.89M
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a
Highlights
CNTX's EPS has surged by 69% year-on-year and by 49% since the previous quarter
The equity is up by 14% since the previous quarter
Context Therapeutics's net income has decreased by 12% YoY but it has increased by 11% from the previous quarter
The quick ratio fell by 6% QoQ
Key stats
What are the main financial stats of CNTX
Market
Valuations
Earnings
Shares outstanding
89.7M
Market cap
$84.32M
Enterprise value
-$9.89M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.74
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$29.93M
Net income
-$26.73M
EBIT
-$26.73M
EBITDA
-$26.67M
Free cash flow
-$14.56M
Per share
Balance sheet
Liquidity
EPS
-$0.46
EPS diluted
-$0.46
Free cash flow per share
-$0.25
Book value per share
$1.27
Revenue per share
$0
TBVPS
$1.68
Total assets
$98.13M
Total liabilities
$2.86M
Debt
$219,380
Equity
$95.27M
Working capital
$95.15M
Debt to equity
0
Current ratio
35.62
Quick ratio
34.36
Net debt/EBITDA
3.53
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-35.8%
Return on equity
-37%
Return on invested capital
N/A
Return on capital employed
-28%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CNTX stock price
How has the Context Therapeutics stock price performed over time
Intraday
-6%
1 week
11.49%
1 month
8.67%
1 year
-31.88%
YTD
-10.48%
QTD
53.59%
Financial performance
How have Context Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.93M
Net income
-$26.73M
Gross margin
N/A
Net margin
N/A
CNTX's operating income is down by 19% year-on-year but it is up by 8% since the previous quarter
Context Therapeutics's net income has decreased by 12% YoY but it has increased by 11% from the previous quarter
Growth
What is Context Therapeutics's growth rate over time
Valuation
What is Context Therapeutics stock price valuation
P/E
N/A
P/B
0.74
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CNTX's EPS has surged by 69% year-on-year and by 49% since the previous quarter
CNTX's P/B is 56% lower than its last 4 quarters average of 1.7
The equity is up by 14% since the previous quarter
Efficiency
How efficient is Context Therapeutics business performance
CNTX's ROE has soared by 68% year-on-year and by 37% since the previous quarter
The ROA has soared by 63% YoY and by 36% QoQ
Dividends
What is CNTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CNTX.
Financial health
How did Context Therapeutics financials performed over time
CNTX's total liabilities is down by 32% year-on-year but it is up by 16% since the previous quarter
Context Therapeutics's total assets has increased by 14% QoQ
CNTX's debt is 100% smaller than its equity
The equity is up by 14% since the previous quarter
CNTX's debt is down by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.